OrganiGram Holdings Inc (OTCMKTS:OGRMF) has entered into a supply pact with 1812 Hemp, an industrial hemp research company based in New Brunswick. The accord also allows R&D on hemp improvement by using traditional breeding methods. 1812 Hemp develops specific varieties of hemp with desirable qualities. It develops the Canadian cultivars of improved CBD yielding hemp that grows in the Canadian Climate.
OrganiGrams gets access to hemp flower with high CBD
The accord allows OrganiGram access to dried hemp flower that has high levels of cannabidiol (4% to 8%). Cannabis and hemp with high levels of CBD offer a lot of therapeutic benefits. Chief Executive Officer of OrganiGram, Greg Engel said the ability to enhance the yield of CBD from cannabis and hemp help to satisfy the growing demand for cannabidiol from consumers while achieving the economies of scale.
He said the company is pleased to collaborate with leading research institutes and companies to explore cannabis plants and hemp potential. The company tries to deliver hemp with high levels of CBD to the consumers. Cannabis legalization in Canada enhanced the need to develop agriculture technologies and engage in R&D on plant breeding to provide support to both outdoor and indoor cultivation of industrial hemp and cannabis. Organigram got access to the 6,000 kg of dried hemp flower produced in fall 2018. The company would gain dried hemp flower and send for extraction in Q1 2019.
1812 Hemp leverages research capacity
1812 Hemp leverages the considerable experience in developing cultivar crop and research capacity as it prepares to introduce hemp breeding program to develop improved and innovative cultivars. It helps to support the growing demand for premium hemp genetics both in the domestic and global markets.
Engel speaking on the development said the company sees an incredible opportunity for the CBD in Canada. The demand for CBD infused products increase in both recreational and medical channels.
OrganiGram Unveils OrganiCare program
OrganiGram introduced OrganiCare program to provide compassionate care to the patients. It aims to provide medical cannabis to the low-income category. The patients with annual income levels of lower than $35,000 are eligible for the OrganiCare Program.